Literature DB >> 23492761

Duration of cisplatin excretion in breast milk.

Karen E Hays1, Rachel J Ryu, Elizabeth M Swisher, Eddie Reed, Terry McManus, Blanche Rybeck, William P Petros, Mary F Hebert.   

Abstract

Cisplatin, a platinum-based chemotherapy agent, is commonly used in treating cancers that may affect women of childbearing age, including cervical cancer, triple-negative breast cancer, and pediatric tumors in adolescents. The authors found that platinum was undetectable in breast milk at 66 hours and beyond following a 70-mg dose of intravenous cisplatin. Relative infant dose of platinum was calculated to be between 0.29% and 0.40% of the maternal dose corrected for body weight. This case demonstrates minimal exposure to platinum via breast milk, following a single 70-mg intravenous dose of cisplatin.

Entities:  

Keywords:  breast milk; breastfeeding; cisplatin; human milk

Mesh:

Substances:

Year:  2013        PMID: 23492761      PMCID: PMC4041270          DOI: 10.1177/0890334413479671

Source DB:  PubMed          Journal:  J Hum Lact        ISSN: 0890-3344            Impact factor:   2.219


  15 in total

1.  Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.

Authors:  Saik Urien; Etienne Brain; Roland Bugat; Xavier Pivot; Isabelle Lochon; Marie-Louise Vo Van; Françoise Vauzelle; François Lokiec
Journal:  Cancer Chemother Pharmacol       Date:  2004-07-28       Impact factor: 3.333

2.  Cisplatin excretion in human milk.

Authors:  G Ben-Baruch; J Menczer; R Goshen; B Kaufman; R Gorodetsky
Journal:  J Natl Cancer Inst       Date:  1992-03-18       Impact factor: 13.506

3.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

Authors:  P G Rose; B N Bundy; E B Watkins; J T Thigpen; G Deppe; M A Maiman; D L Clarke-Pearson; S Insalaco
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

4.  Breastfeeding and the use of human milk.

Authors:  Lawrence M Gartner; Jane Morton; Ruth A Lawrence; Audrey J Naylor; Donna O'Hare; Richard J Schanler; Arthur I Eidelman
Journal:  Pediatrics       Date:  2005-02       Impact factor: 7.124

5.  Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding.

Authors:  Bernard Royer; Emmanuel Guardiola; Emmanuel Polycarpe; Guillaume Hoizey; Delphine Delroeux; Marielle Combe; Loïc Chaigneau; Emmanuel Samain; Bruno Chauffert; Bruno Heyd; Jean-Pierre Kantelip; Xavier Pivot
Journal:  Anticancer Drugs       Date:  2005-10       Impact factor: 2.248

6.  Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study.

Authors:  Rachelle Lanciano; Alison Calkins; Brian N Bundy; Groesbeck Parham; Joseph A Lucci; David H Moore; Bradley J Monk; Dennis M O'Connor
Journal:  J Clin Oncol       Date:  2005-10-17       Impact factor: 44.544

7.  Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II study.

Authors:  C B Pratt; A Hayes; A A Green; W E Evans; N Senzer; C B Howarth; J L Ransom; W Crom
Journal:  Cancer Treat Rep       Date:  1981 Nov-Dec

8.  Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.

Authors:  H M Keys; B N Bundy; F B Stehman; L I Muderspach; W E Chafe; C L Suggs; J L Walker; D Gersell
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

9.  Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.

Authors:  Peter G Rose; Shamshad Ali; Edwin Watkins; J Tate Thigpen; Gunter Deppe; Daniel L Clarke-Pearson; Samuel Insalaco
Journal:  J Clin Oncol       Date:  2007-05-14       Impact factor: 44.544

10.  Doxorubicin and cisplatin excretion into human milk.

Authors:  P C Egan; M E Costanza; P Dodion; M J Egorin; N R Bachur
Journal:  Cancer Treat Rep       Date:  1985-12
View more
  3 in total

Review 1.  Biological barriers, and the influence of protein binding on the passage of drugs across them.

Authors:  Karolina Wanat
Journal:  Mol Biol Rep       Date:  2020-03-05       Impact factor: 2.316

Review 2.  Inclusion of pregnant and breastfeeding women in research - efforts and initiatives.

Authors:  Sílvia M Illamola; Christina Bucci-Rechtweg; Maged M Costantine; Ekaterini Tsilou; Catherine M Sherwin; Anne Zajicek
Journal:  Br J Clin Pharmacol       Date:  2017-10-22       Impact factor: 4.335

3.  Effect of chemotherapy on the microbiota and metabolome of human milk, a case report.

Authors:  Camilla Urbaniak; Amy McMillan; Michelle Angelini; Gregory B Gloor; Mark Sumarah; Jeremy P Burton; Gregor Reid
Journal:  Microbiome       Date:  2014-07-11       Impact factor: 14.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.